Dr. Goodenow has over 20 years of experience in the biopharmaceutical industry spanning R&D, product launch, marketing, intellectual property, and business development for drugs and drug-device combinations. He was formerly Vice President of Corporate Development for Inovio Biomedical Corporation, where he was responsible for partnering and commercialization of the company’s oncology and vaccine platforms. He also held key management positions at Aventis in both Corporate Marketing and Business Development for Oncology during the initial commercialization of Taxotere®, as well as in R&D for Baxter Biotech. Dr. Goodenow received his BA in Biochemistry from the University of California Berkeley, a PhD in Biophysics from Stanford University, and postdoctoral training at Caltech in the Division of Biology.